ロード中...
Advances in HER2-Positive Breast Cancer: Novel Therapies and Adverse Event Management
Although breast cancer is a heterogeneous disease, approximately 20% to 25% of patients diagnosed with breast cancer have amplification of the HER2 gene. The FDA approval of trastuzumab for the treatment of HER2-positive (HER2+) metastatic breast cancer in 1998 represented a major breakthrough for p...
保存先:
| 出版年: | J Adv Pract Oncol |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Harborside Press
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6750923/ https://ncbi.nlm.nih.gov/pubmed/31538025 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|